Brief: Silo Pharma Inc - Advancing Development Of Spu-21 Liposomal Joint Homing Peptides In Collaboration With University Of Maryland, Baltimore
30/05/2023 14:01
May 30 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA INC - ADVANCING DEVELOPMENT OF SPU-21
LIPOSOMAL
JOINT HOMING PEPTIDES IN COLLABORATION WITH UNIVERSITY OF
MARYLAND, BALTIMORE
Source text for Eikon: ID:nGNX5GqM9
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement